RhumbLine Advisers
TMCI icon

RhumbLine Advisers’s Treace Medical Concepts TMCI Stock Holding History

RhumbLine Advisers’s Portfolio TMCI Stock Details TMCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$40.4K Sell
10,159
-47,340
-82% -$130K ﹤0.01% 3716
2026
Q1 		$77K Sell
57,499
-2,418
-4% -$4.82K ﹤0.01% 3502
2025
Q4 		$147K Sell
59,917
-19,614
-25% -$85.2K ﹤0.01% 3311
2025
Q3 		$534K Buy
79,531
+8,893
+13% +$58.1K ﹤0.01% 2655
2025
Q2 		$415K Buy
70,638
+722
+1% +$4.7K ﹤0.01% 2799
2025
Q1 		$587K Buy
69,916
+3,843
+6% +$34.5K ﹤0.01% 2473
2024
Q4 		$492K Buy
66,073
+1,300
+2% +$8.7K ﹤0.01% 2691
2024
Q3 		$376K Sell
64,773
-28,076
-30% -$180K ﹤0.01% 2896
2024
Q2 		$617K Buy
92,849
+31,281
+51% +$253K ﹤0.01% 2522
2024
Q1 		$803K Buy
61,568
+1,208
+2% +$16.1K ﹤0.01% 2376
2023
Q4 		$770K Sell
60,360
-479
-0.8% -$4.84K ﹤0.01% 2412
2023
Q3 		$798K Buy
60,839
+2,123
+4% +$38.9K ﹤0.01% 2337
2023
Q2 		$1.5M Buy
58,716
+10,559
+22% +$273K ﹤0.01% 2068
2023
Q1 		$1.21M Buy
48,157
+5,386
+13% +$126K ﹤0.01% 2040
2022
Q4 		$983K Buy
42,771
+1,054
+3% +$24.3K ﹤0.01% 2138
2022
Q3 		$921K Buy
41,717
+3,338
+9% +$64.6K ﹤0.01% 2172
2022
Q2 		$550K Buy
38,379
+9,640
+34% +$162K ﹤0.01% 2456
2022
Q1 		$543K Buy
28,739
+7,673
+36% +$149K ﹤0.01% 2392
2021
Q4 		$393K Buy
21,066
+13,061
+163% +$270K ﹤0.01% 2606
2021
Q3 		$215K Buy
8,005
+525
+7% +$14.4K ﹤0.01% 2886
2021
Q2 		$234K Buy
+7,480
New +$238K ﹤0.01% 2878

Other funds holding TMCI

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GA
Gagnon Advisors New York $157M AUM 36.77% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
CBU
CIBC Bancorp USA Chicago, Illinois $82.3B AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

RhumbLine Advisers's TMCI Position: Q2 2026 in Review

RhumbLine Advisers reduced its Treace Medical Concepts (TMCI) stake by 82% in Q2 2026, selling an estimated $130K and leaving 10,159 shares worth $40.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3716.

RhumbLine Advisers first reported a position in TMCI in Q2 2021 and has held it in 21 quarters since. The position peaked at $1.5M in Q2 2023. 116 funds tracked by Wall St. Rank hold TMCI as of Q2 2026.

  • RhumbLine Advisers held 10,159 shares of Treace Medical Concepts worth $40.4K as of Q2 2026.
  • RhumbLine Advisers sold 47,340 Treace Medical Concepts shares in Q2 2026, an estimated $130K.
  • Treace Medical Concepts made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3716 holding.
  • RhumbLine Advisers first reported a position in Treace Medical Concepts in Q2 2021 and has held it in 21 quarters since.
  • RhumbLine Advisers's Treace Medical Concepts position peaked at $1.5M in Q2 2023.
  • 116 funds tracked by Wall St. Rank held Treace Medical Concepts as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.